Late treatment study
Nanshan (钟南山) (News) (not included in the study count)
Efficacy and safety of ch loroquine for treatment of COVID-19. An open-label, multi-center, non-randomized trial
197 patients. HC Q effective. Viral RNA negative in 95.9% versus 79.6% control. Median time to negative tests 3 days versus 9 days for control.
Currently no formal study is available so this is not included in the study count.
Please send us corrections, updates, or comments.